SCHEMBL6209517

SCHEMBL6209517

CCc1cc(C(=O)O)c[nH]c1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.53
ALDH1A1 P00352 2/20 0.39
DAO P14920 2/20 0.39
DYRK1A Q13627 1/20 0.39
TDP1 Q9NUW8 1/20 0.38
RXRA P19793 1/20 0.37
RXRB P28702 1/20 0.37
GRIN2D O15399 1/20 0.36
GRIN3B O60391 1/20 0.36
GRIN1 Q05586 1/20 0.36
GRIN2A Q12879 1/20 0.36
GRIN2B Q13224 1/20 0.36
GRIN2C Q14957 1/20 0.36
GRIN3A Q8TCU5 1/20 0.36
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
KMT2A Q03164 1/20 0.35
TPMT P51580 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6207336 0.87 NOTUM (0.48) NOTUMALDH1A1DYRK1ATDP1RXRA
SCHEMBL4649101 0.83 GRIN2D (0.35) NOTUMALDH1A1DAODYRK1AGRIN2D
SCHEMBL8705694 0.82 RARB (0.44) NOTUMALDH1A1MEN1KMT2AHCAR2
SCHEMBL14334050 0.81 NOTUM (0.46) NOTUMALDH1A1DAODYRK1ATDP1
SCHEMBL14333162 0.81 NOTUM (0.46) NOTUMALDH1A1DAODYRK1ATDP1
SCHEMBL4649373 0.81 NOTUM (0.42) NOTUMALDH1A1DYRK1ATDP1MEN1
SCHEMBL4648846 0.80 NOTUM (0.44) NOTUMALDH1A1DAODYRK1ATDP1
SCHEMBL22623624 0.79 CA12 (0.47) ALDH1A1KDM4EMEN1NPC1KMT2A
SCHEMBL6207170 0.79 NOTUM (0.43) NOTUMALDH1A1DYRK1ATDP1KDM4E
SCHEMBL14604111 0.78 GAA (0.45) NOTUMDAOKDM4EMEN1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1546133-A2 N-SUBSTITUTE-2-OXODIHYDROPYRIDINE DERIVATIVES AS NPY ANTAGONISTS BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-06-29 EP disclosed
WO-2004031175-A2 N-SUBSTITUTED-2-OXODIHYDROPYRIDINE DERIVATIVES AS NPY ANTAGONISTS BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-04-15 WO disclosed
US-6670380-B2 For therapy of insulin resistance, hyperglycemia, hyperinsulinemia, or elevated blood levels of free fatty acids or glycerol, obesity, hypertriglyceridemia, inflammation, atherosclerosis, diabetic retinopathy, diabetic neuropathy BRISTOL-MYERS SQUIBB CO. 2003-12-30 US disclosed
EP-1343763-A1 PYRODONE DERIVATIVES AS AP2 INHIBITORS Bristol-Myers Squibb Company (US) 2003-09-17 EP disclosed
US-20020077340-A1 Pyridone inhibitors of fatty acid binding protein and method BRISTOL-MYERS SQUIBB COMPANY 2002-06-20 US disclosed
WO-2002040448-A1 PYRIDONE DERIVATIVES AS AP2 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2002-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020077340-A1 Pyridone inhibitors of fatty acid binding protein and method FABP1, FABP5, FABP2 NOTUM 1648/4885ALDH1A1 1579/4885DAO 2624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.